摘要
目的观察急性ST段抬高型心肌梗死(STEMI)患者术前使用替罗非班对择期经皮冠状动脉介入治疗(PCI)术时梗死相关动脉(IRA)前向血流恢复、不良事件及出血率的影响。方法选择2014年2月至2015年1月延安大学咸阳医院收治的70例急性STEMI患者,随机分为替罗非班组和对照组,各35例。两组患者术前均给予双重抗血小板治疗,替罗非班组连续静脉微量泵入替罗非班48 h,对照组患者给予常规药物治疗。观察两组患者的IRA前向血流、住院期间主要心血管不良事件(MACE)发生情况及出血情况。结果替罗非班组患者的IRA前向血流TIMI分级优于对照组,MACE总发生率明显低于对照组(P<0.05)。两组患者出血率比较,差异不显著(P>0.05)。结论 STEMI患者PCI术前使用替罗非班可以明显改善IRA前向血流恢复情况,减少住院期间MACE的发生,安全性良好。
Objective To observe the effect of preoperative tirofiban on preoperative infarct -related arterial （IRA）anterior blood flow recovery in percutaneous coronary intervention （PCI）, adverse events and bleeding in patients with acuteST -segment elevation myocardial infarction （STEMI）. Methods Seventy patients with acute STEMI who admitted toXianyang Hospital of Yan＇an University from February 2014 to January 2015 were randomly divided into tirofiban groupand control group, with 35 cases in each group. Patients were treated with dual antiplatelet therapy before operation. Thepatients in the tirofiban group were treated with continuous intravenous microinfusion of tirofiban for 48 h. The controlgroup received conventional drug therapy. The IRA anterior blood flow, major adverse cardiac events （MACE） duringhospitalization and bleeding in the two groups were observed. Results The IRA antegrade blood flow TIMI grading in thetirofiban group was better than that in the control group, the total incidence of MACE was significantly lower than that inthe control group （P〈0.05）. The bleeding rates of the two groups were not significantly different（P〉0.05）. ConclusionPreoperative use of tirofiban in patients with STEMI can significantly improve IRA anterior blood flow recovery, reduce theoccurrence of MACE during hospitalization, with good safety.
作者
赵娟
陈宁
王芝荣
左梅
李新国
ZHAO Juan;CHEN Ning;WANG Zhi-rong;ZUO Mei;LI Xin-guo(Xianyang Hospital of Yan＇an University,Xianyang 712000;the People＇s Hospital of Yangling Demonstration Zone,Xianyang 712100,China)
出处
《临床医学研究与实践》
2018年第27期67-69,共3页
Clinical Research and Practice
作者简介
赵娟（1980-）,女,汉族,陕西咸阳人,副主任医师,硕士.研究方向：冠心病的介入治疗.;通讯作者：李新国,E-mail：921737619@qq.com.
